Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
Top Cited Papers
Open Access
- 14 December 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 16 (4), 653-664
- https://doi.org/10.1016/j.jtho.2020.11.025
Abstract
No abstract availableFunding Information
- F. Hoffmann-La Roche
This publication has 20 references indexed in Scilit:
- Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for AtezolizumabApplied Immunohistochemistry & Molecular Morphology, 2019
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2016
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1Clinical Cancer Research, 2012
- A group sequential Holm procedure with multiple primary endpointsStatistics in Medicine, 2012
- The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Cisplatin augments cytotoxic T-lymphocyte–mediated antitumor immunity in poorly immunogenic murine lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2003